Related Experiment Video
Updated: Aug 26, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.0K
Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction
Anthony E Peters1, Adam D DeVore1
1Division of Cardiology, Duke University School of Medicine, Duke University Medical Center, 200 Trent Drive, 4th Floor, Orange Zone, Room #4225, Durham, NC 27710, USA; Duke Clinical Research Institute, Duke University Medical Center, 200 Trent Drive, 4th Floor, Orange Zone, Room #4225, Durham, NC 27710, USA.
Cardiology Clinics
|October 9, 2022
Summary
Managing heart failure with preserved ejection fraction (HFpEF) involves symptom control and treating related conditions. Certain medications effectively reduce hospitalizations for HFpEF patients.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Heart failure with preserved ejection fraction (HFpEF) management is a dynamic clinical area.
- Current treatment focuses on symptom relief and managing comorbidities like hypertension, obesity, diabetes, and atrial fibrillation.
Purpose of the Study:
- To review current pharmacologic strategies for HFpEF.
- To highlight therapies that reduce HF hospitalizations.
Main Methods:
- Review of current literature and clinical trial data on HFpEF pharmacotherapy.
- Analysis of treatment outcomes including symptom management and hospitalization rates.
Main Results:
- Diuretics are key for symptom management in HFpEF.
- Optimizing comorbidities is crucial for effective HFpEF care.
- Angiotensin II receptor blockers, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors, and SGLT-2 inhibitors show promise in reducing HF hospitalizations, especially in specific patient subgroups.
Conclusions:
- Specific pharmacotherapies offer benefits in reducing HF hospitalizations for HFpEF patients.
- Further research and ongoing trials are essential to refine optimal HFpEF treatment strategies.
Related Concept Videos
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
488
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
488
01:22Heart Failure VI: Adjunct Therapies
25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
01:22Heart Failure Drugs: Diuretics
457
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
457
01:22Heart Failure Drugs: β-Blockers
418
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
418
01:26Heart Failure Drugs: Inotropic Agents
688
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
688